Abstract: Provided herein are synthetic, three-dimensional (3D) bioprinted tissue constructs comprising porcine cells and methods of producing and using the same. The synthetic 3D bioprinted tissue constructs are fabricated by bioprinting spheroids comprising porcine cells, including genetically engineered cells, on a microneedle mold and fusing the spheroids to form an engineered tissue construct. Also provided are methods of using scaffold-free 3D bioprinted tissue constructs for applications related to drug screening and toxicity screening.
Type:
Grant
Filed:
October 17, 2018
Date of Patent:
October 25, 2022
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Abstract: A technology regarding the production, formulation and use of conditioned media and the factors included therein is disclosed. The conditioned media may be inoculated with animal cells, plant cells and any combination thereof. The inoculations may occur simultaneous or at different times. Cells retrieved from different areas of the animal and/or the plant may also be cultured together to form conditioned media and associated growth factors.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
October 18, 2022
Assignee:
Rinati Skin, LLC
Inventors:
Nathan Newman, Alex Rajangam, Dodanim Talavera-Adame, Harpreet Sidhu
Abstract: In some embodiments, the present invention provides tissue grafts, such as vascularized bone grafts, and methods for preparing and using such tissue grafts. In some embodiments the tissue grafts are made using pluripotent stem cells, such as autologous pluripotent stem cells. In some embodiments, the tissue grafts are made by creating a digital model of a tissue portion to be replaced or repaired, such as a bone defect, partitioning the model into two or more model segments, and then producing tissue graft segments having a size and shape corresponding to that of the model segments. Such tissue graft segments may be assembled to form a tissue graft having a size and shape corresponding to that of the tissue portion to be replaced or repaired.
Abstract: A method is provided for producing a live cartilaginous material useful for implantation into a patient. A method of treating a patient comprising implanting a cartilaginous material prepared according to the provided method in an anatomical site in a patient also is provided.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
October 18, 2022
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Hang Lin, Rocky Sung Chi Tuan, Yuanheng Yang
Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
October 18, 2022
Assignees:
SUMITOMO CHEMICAL COMPANY, LIMITED, RIKEN
Abstract: An object of the present invention is to provide an angiogenic agent that can sufficiently exhibit an angiogenic effect due to mesenchymal stem cells in a state where the angiogenic agent does not allow permeation of host cells while being protected from immune rejection, and a method for method for manufacturing the same. According to the present invention, an angiogenic agent including a mesenchymal stem cell (A); and an immunoisolation membrane (B) that encloses the mesenchymal stem cell is provided.
Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
October 18, 2022
Assignee:
Vivex Biologics Group, Inc.
Inventors:
Timothy Ganey, Wendy W. Weston, Miguel Quevedo, Stuart Oglesby, Tracy Scott Anderson
Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
Type:
Grant
Filed:
October 25, 2021
Date of Patent:
October 18, 2022
Assignees:
XenoTherapeutics, Inc., Alexis Bio, Inc.
Inventors:
Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
Abstract: Provided is a method for producing a three-dimensional tissue having a vascular system structure, said method comprising: (a) a step for forming a vascular system structure template using a gel; (b) a step for forming a three-dimensional tissue in the vicinity of the template; (c) a step for dissolving the template using a cationic solution; and (d) a step for seeding vascular endothelial cells and/or lymphatic vessel endothelial cells in a void remaining after the dissolution of the template. Also provided is a method for producing a three-dimensional tissue having a vascular system structure, said method comprising: (i) a step for forming a vascular system structure template using a gel; (ii) a step for seeding vascular endothelial cells and/or lymphatic vessel endothelial cells on the template; (iii) a step for forming a three-dimensional tissue in the vicinity of the cells seeded above; and (iv) a step for dissolving the template using a cationic solution.
Abstract: Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity are for in production of advanced therapeutic medicinal products. In certain examples, term amniotic fluid derived cells having characteristics of lung cells can be isolated. In some the term amniotic fluid derived cells having characteristics of lung cells can be used in the treatment of acute and chronic respiratory diseases.
Type:
Grant
Filed:
December 30, 2021
Date of Patent:
September 20, 2022
Assignee:
AMNIOTICS AB
Inventors:
Jan Talts, Niels-Bjarne Woods, Kare Engkilde, Marcus Larsson
Abstract: Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cell-free” therapeutic candidate for tissue repair.
Abstract: A mycological biopolymer product consisting entirely of fungal mycelium is made by inoculating a nutritive substrate with a selected fungus in a sealed environment except for a void space, which space is subsequently filled with a network of undifferentiated fungal mycelium. The environmental conditions for producing the mycological biopolymer product, i.e. a high carbon dioxide (CO2) content (from 5% to 7% by volume) and an elevated temperature (from 85° F. to 95° F.), prevent full differentiation of the fungus into a mushroom. There are no stipe, cap, or spores produced. The biopolymer product grows into the void space of the tool, filling the space with an undifferentiated mycelium chitin-polymer, which is subsequently extracted from the substrate and dried.
Type:
Grant
Filed:
July 21, 2014
Date of Patent:
March 22, 2022
Assignee:
Ecovative Design LLC
Inventors:
Lucy Greetham, Gavin R. McIntyre, Eben Bayer, Jacob Winiski, Sarah Araldi
Abstract: An object of the invention is to provide a cartilage regenerative material that is capable of regenerating bone and cartilage using cells. Provided is a cartilage regenerative material including a cell construct, which includes biocompatible polymer blocks and stem cells, in which a plurality of the biocompatible polymer blocks are disposed in gaps between a plurality of the stem cells.
Type:
Grant
Filed:
October 22, 2019
Date of Patent:
February 8, 2022
Assignees:
FUJIFILM Corporation, JAPAN TISSUE ENGINEERING CO., LTD.
Abstract: In one embodiment, the present invention relates to a non-enzymatic method for isolating stem cells from adipose tissue, wherein the method comprises treating adipose tissue with ultrasonic cavitation to break up the adipose tissue and lyses mature adipocytes, resulting in a stromal vascular fraction containing viable stromal/stem cells.
Type:
Grant
Filed:
June 26, 2018
Date of Patent:
February 1, 2022
Assignee:
Cell-Innovations IP Pty Ltd
Inventors:
Ralph Bright, Pelin Bright, Bruce Hansen, Wayne Thomas
Abstract: The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.
Type:
Grant
Filed:
January 15, 2020
Date of Patent:
January 25, 2022
Assignee:
ALLOSOURCE
Inventors:
Reginald L. Stilwell, Brent Atkinson, Yaling Shi, Brian Dittman
Abstract: Processing and use of fluids from the reproductive tract (biofluids) to improve the in vitro production of mammalian embryos comprising the following steps: a) fractionation and processing of biofluids through a sorting, purification, lyophilization and subsequent storage; b) a method of sperm capacitation in a culture medium supplemented with biofluids; c) in vitro fertilization in a medium enriched with biofluids and d) subsequent in vitro culture with development of the obtained embryos to any stage of preimplantational development in culture media supplemented with biofluids.
Type:
Grant
Filed:
October 7, 2015
Date of Patent:
December 28, 2021
Assignee:
UNIVERSIDAD DE MURCIA
Inventors:
Raquel Romar Andres, Maria Pilar Coy Fuster
Abstract: The invention relates to an artificial cell system comprising at least one droplet-interface bilayer (DIB) encased within a shell; a suspension comprising same; and a method and a device for the manufacture of same.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
December 28, 2021
Assignee:
UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD
Inventors:
Oliver Castell, David Barrow, Divesh Baxani